請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24215
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳建仁 | |
dc.contributor.author | Yi-Chu Chen | en |
dc.contributor.author | 陳薏竹 | zh_TW |
dc.date.accessioned | 2021-06-08T05:18:43Z | - |
dc.date.copyright | 2005-08-12 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-29 | |
dc.identifier.citation | 1. Waggoner, S.E., Cervical cancer. Lancet, 2003. 361(9376): p. 2217-25.
2. Smith, J.S., et al., Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet, 2003. 361(9364): p. 1159-67. 3. 行政院衛生署, Editor. 2003, 91年衛生統計重要指標. 4. Franceschi, S., The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results in Cancer Research, 2005. 166: p. 277-97. 5. Walboomers, J.M., et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology, 1999. 189(1): p. 12-9. 6. Schiffman, M. and P. Castle, Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. Journal of the National Cancer Institute., 2003. 95(6): p. E2. 7. Bosch, F.X., et al., The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology, 2002. 55(4): p. 244-65. 8. Haverkos, H., M. Rohrer, and W. Pickworth, The cause of invasive cervical cancer could be multifactorial. Biomedicine & Pharmacotherapy, 2000. 54(1): p. 54-9. 9. Ibbotson, T. and S. Wyke, A review of cervical cancer and cervical screening: implications for nursing practice. Journal of Advanced Nursing, 1995. 22(4): p. 745-52. 10. Moscicki, A.B., et al., Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA, 2001. 285(23): p. 2995-3002. 11. Schiff, M., et al., Risk factors for cervical intraepithelial neoplasia in southwestern American Indian women. American Journal of Epidemiology, 2000. 152(8): p. 716-26. 12. Thomas, D.B., et al., Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. American Journal of Epidemiology, 2001. 153(8): p. 732-9. 13. Green, J., et al., Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. British Journal of Cancer, 2003. 89(11): p. 2078-86. 14. Skrabanek, P., Cervical cancer in nuns and prostitutes: a plea for scientific continence. Journal of Clinical Epidemiology, 1988. 41(6): p. 577-82. 15. Castellsague, X., et al., Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. New England Journal of Medicine, 2002. 346(15): p. 1105-12. 16. Bosch, F.X., Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica de Mexico, 2003. 45 Suppl 3: p. S326-39. 17. Bayo, S., et al., Risk factors of invasive cervical cancer in Mali. International Journal of Epidemiology, 2002. 31(1): p. 202-9. 18. Castle, P.E., et al., A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. Journal of the National Cancer Institute, 2002. 94(18): p. 1406-14. 19. Szarewski, A., et al., Effect of smoking cessation on cervical lesion size. Lancet, 1996. 347(9006): p. 941-3. 20. Anonymous, Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. International Journal of Cancer, 1993. 55(2): p. 228-36. 21. Schiffman, M. and P.E. Castle, Human papillomavirus: epidemiology and public health. Archives of Pathology & Laboratory Medicine, 2003. 127(8): p. 930-4. 22. Castellsague, X. and N. Munoz, Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. Journal of the National Cancer Institute, 2003. Monographs.(31): p. 20-8. 23. Brinton, L.A., et al., Parity as a risk factor for cervical cancer. American Journal of Epidemiology, 1989. 130(3): p. 486-96. 24. Munoz, N., et al., Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet, 2002. 359(9312): p. 1093-101. 25. Crum, C.P. and J.K. Roche, Papillomavirus-related genital neoplasia: present and future prevention. Cancer Detection & Prevention, 1990. 14(4): p. 465-9. 26. zur Hausen, H., Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. Journal of the National Cancer Institute, 2000. 92(9): p. 690-8. 27. Munoz, N., et al., Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 2003. 348(6): p. 518-27. 28. Dillner, J., et al., Prospective Seroepidemiologic Study of Human Papillomavirus Infection as a Risk Factor for Invasive Cervical Cancer. Journal of the National Cancer Institute, 1997. 89(17): p. 1293-1299. 29. Santos, C., et al., HPV types and cofactors causing cervical cancer in Peru. British Journal of Cancer, 2001. 85(7): p. 966-71. 30. Nindl, I., et al., Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay. Journal of Clinical Pathology, 1999. 52(1): p. 17-22. 31. Castellsague, X., F.X. Bosch, and N. Munoz, Environmental co-factors in HPV carcinogenesis. Virus Research, 2002. 89(2): p. 191-199. 32. Villa, L.L., Human papillomaviruses and cervical cancer. Advances in Cancer Research, 1997. 71: p. 321-41. 33. Rozendaal, L., et al., PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. International Journal of Cancer, 1996. 68(6): p. 766-9. 34. Moscicki, A.B., et al., The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. Journal of Pediatrics, 1998. 132(2): p. 277-84. 35. Liaw, K.L., et al., Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. Journal of the National Cancer Institute, 1999. 91(11): p. 954-60. 36. Hildesheim, A., et al., Persistence of type-specific human papillomavirus infection among cytologically normal women. Journal of Infectious Diseases, 1994. 169(2): p. 235-40. 37. Evander, M., et al., Human papillomavirus infection is transient in young women: a population-based cohort study. Journal of Infectious Diseases, 1995. 171(4): p. 1026-30. 38. Ho, G.Y., et al., Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine, 1998. 338(7): p. 423-8. 39. Ho, G.Y., et al., Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. Journal of the National Cancer Institute, 1995. 87(18): p. 1365-71. 40. Schlecht, N.F., et al., Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. Jama, 2001. 286(24): p. 3106-14. 41. Wang, Z.H., et al., Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. Journal of Infectious Diseases, 2000. 181(2): p. 456-62. 42. Lehtinen, M., et al., Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. Bmj, 1996. 312(7030): p. 537-9. 43. Vonka, V., et al., Prospective study on cervical neoplasia IV. Presence of HPV antibodies. International Journal of Cancer, 1999. 80(3): p. 365-8. 44. Shah, K.V., et al., Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiology, Biomarkers & Prevention, 1997. 6(4): p. 233-7. 45. Pham, T.H., et al., Human papillomavirus infection among women in South and North Vietnam. International Journal of Cancer, 2003. 104(2): p. 213-20. 46. Tarkowski, T.A., et al., Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. Journal of Infectious Diseases, 2004. 189(1): p. 46-50. 47. Munoz, N., et al., Risk factors for HPV DNA detection in middle-aged women. Sexually Transmitted Diseases, 1996. 23(6): p. 504-10. 48. Giuliano, A.R., et al., Risk factors for high-risk type human papillomavirus infection among Mexican-American women. Cancer Epidemiology, Biomarkers & Prevention, 1999. 8(7): p. 615-20. 49. Sellors, J.W., et al., Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ Canadian Medical Association Journal, 2000. 163(5): p. 503-8. 50. Herrero, R., et al., Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. Journal of the National Cancer Institute, 2000. 92(6): p. 464-74. 51. Richardson, H., et al., Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sexually Transmitted Diseases, 2000. 27(2): p. 79-86. 52. Lazcano-Ponce, E., et al., Epidemiology of HPV infection among Mexican women with normal cervical cytology. International Journal of Cancer, 2001. 91(3): p. 412-20. 53. Molano, M., et al., Prevalence and determinants of HPV infection among Colombian women with normal cytology. British Journal of Cancer, 2002. 87(3): p. 324-33. 54. Chan, P.K.S., et al., Determinants of cervical Human papillomavirus infection: Differences between high and low oncogenic risk types. The Journal of Infectious Diseases, 2002. 185(1): p. 28-35. 55. Shin, H.R., et al., Prevalence of human papillomavirus infection in women in Busan, South Korea. International Journal of Cancer, 2003. 103(3): p. 413-21. 56. Sukvirach, S., et al., Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. Journal of Infectious Diseases, 2003. 187(8): p. 1246-56. 57. Shin, H.R., et al., Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. Journal of Infectious Diseases, 2004. 190(3): p. 468-76. 58. Ronco, G., et al., Prevalence of human papillomavirus infection in women in Turin, Italy. European Journal of Cancer, 2005. 41(2): p. 297-305. 59. 游山林, 台灣地區子宮頸癌之流行病學研究 (未發表之博士論文). 1997. 60. Liaw, K.L., et al., Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. International Journal of Cancer, 1995. 62(5): p. 565-71. 61. Clifford, G.M., et al., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer, 2003. 88(1): p. 63-73. 62. Koutsky, L.A., et al., A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine, 2002. 347(21): p. 1645-51. 63. Richardson, H., et al., The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev, 2003. 12(6): p. 485-490. 64. Schiffman, M.H., Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. Journal of the National Cancer Institute, 1992. 84(6): p. 394-8. 65. Chichareon, S., et al., Risk factors for cervical cancer in Thailand: a case-control study. Journal of the National Cancer Institute, 1998. 90(1): p. 50-7. 66. Ngelangel, C., et al., Causes of cervical cancer in the Philippines: a case-control study. Journal of the National Cancer Institute., 1998. 90(1): p. 43-49. 67. Zeidel, A., et al., Immune response in asymptomatic smokers. Acta Anaesthesiologica Scandinavica, 2002. 46(8): p. 959-64. 68. Yovel, G., et al., Higher natural killer cell activity in schizophrenic patients: the impact of serum factors, medication, and smoking. Brain, Behavior, & Immunity, 2000. 14(3): p. 153-69. 69. Bijl, M., et al., Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. European Journal of Clinical Investigation, 2001. 31(6): p. 550-3. 70. Kalra, R., et al., Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. Journal of Pharmacology & Experimental Therapeutics, 2000. 293(1): p. 166-71. 71. Sopori, M., Effects of cigarette smoke on the immune system. Nature Reviews Immunology, 2002. 2(5): p. 372-7. 72. Moszczynski, P., et al., Immunological findings in cigarette smokers. Toxicology Letters, 2001. 118(3): p. 121-7. 73. Elfgren, K., et al., A population-based five-year follow-up study of cervical human papillomavirus infection. American Journal of Obstetrics & Gynecology, 2000. 183(3): p. 561-7. 74. Burk, R.D., et al., Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. Journal of Infectious Diseases, 1996. 174(4): p. 679-89. 75. Kjaer, S.K., et al., Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiology, Biomarkers & Prevention, 1997. 6(10): p. 799-805. 76. Wheeler, C.M., et al., Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sexually Transmitted Diseases, 1993. 20(5): p. 286-9. 77. Giulian, A.R., et al., Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes & Control., 2002. 13(9): p. 839-846. 78. Duggan, M.A., et al., The natural history of CIN I lesions. European Journal of Gynaecological Oncology, 1998. 19(4): p. 338-44. 79. Guerreiro, D., M.A. Gigante, and L.C. Teles, Sexually transmitted diseases and reproductive tract infections among contraceptive users. International Journal of Gynaecology & Obstetrics, 1998. Suppl 1: p. S167-73. 80. Peters, R.K., et al., Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. Journal of the National Cancer Institute, 1986. 77(5): p. 1063-77. 81. Scholes, D., et al., Vaginal douching as a risk factor for cervical Chlamydia trachomatis infection. Obstetrics & Gynecology, 1998. 91(6): p. 993-7. 82. Ness, R.B., et al., Douching and endometritis: results from the PID evaluation and clinical health (PEACH) study. Sexually Transmitted Diseases, 2001. 28(4): p. 240-5. 83. Zhang, J., A.G. Thomas, and E. Leybovich, Vaginal douching and adverse health effects: a meta-analysis. American Journal of Public Health, 1997. 87(7): p. 1207-11. 84. La Ruche, G., et al., Vaginal douching: association with lower genital tract infections in African pregnant women. Sexually Transmitted Diseases, 1999. 26(4): p. 191-6. 85. Joesoef, M.R., et al., Douching and sexually transmitted diseases in pregnant women in Surabaya, Indonesia. American Journal of Obstetrics & Gynecology, 1996. 174(1 Pt 1): p. 115-9. 86. Franco, E., Understanding the epidemiology of genital infection with oncogenic and nononcogenic human papillomaviruses: a promising lead for primary prevention of cervical cancer. Cancer Epidemiology, Biomarkers & Prevention, 1997. 6(10): p. 799-805. 87. Cauley, J.A., et al., The epidemiology of serum sex hormones in postmenopausal women. American Journal of Epidemiology, 1989. 129(6): p. 1120-31. 88. Siiteri, P.K., Adipose tissue as a source of hormones. American Journal of Clinical Nutrition, 1987. 45(1 Suppl): p. 277-82. 89. Verkasalo, P.K., et al., Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom). Cancer Causes & Control, 2001. 12(1): p. 47-59. 90. Ho, G.Y., et al., Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev, 2004. 13(1): p. 110-116. 91. Mork, J., et al., Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine, 2001. 344(15): p. 1125-1131. 92. Jalal, H., et al., Detection of human papilloma virus type 16 DNA in oral squames from normal young adults. Journal of oral pathology and medicine., 1992. 21(10): p. 465-470. 93. Rostad, B., B. Schei, and F. da Costa, Risk factors for cervical cancer in Mozambican women. International Journal of Gynaecology & Obstetrics, 2003. 80(1): p. 63-5. 94. Harris, T.G., et al., Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. American Journal of Epidemiology, 2004. 159(9): p. 834-42. 95. Silins, I., et al., A population-based study of cervical carcinoma and HPV infection in Latvia. Gynecologic Oncology, 2004. 93(2): p. 484-92. 96. Goodman, M.T., et al., CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecologic Oncology, 2001. 81(2): p. 263-9. 97. Holly, E.A., et al., Mutagenic mucus in the cervix of smokers. Journal of the National Cancer Institute, 1986. 76(6): p. 983-6. 98. Palan, P.R., et al., Effects of smoking and oral contraception on plasma beta-carotene levels in healthy women. American Journal of Obstetrics & Gynecology, 1989. 161(4): p. 881-5. 99. Nierenberg, D.W., et al., Determinants of plasma levels of beta-carotene and retinol. Skin Cancer Prevention Study Group. American Journal of Epidemiology, 1989. 130(3): p. 511-21. 100. Heimburger, D.C., Localized deficiencies of folic acid in aerodigestive tissues. Annals of the New York Academy of Sciences, 1992. 669: p. 87-95; discussion 95-6. 101. Smith, J.L. and R.E. Hodges, Serum levels of vitamin C in relation to dietary and supplemental intake of vitamin C in smokers and nonsmokers. Annals of the New York Academy of Sciences, 1987. 498: p. 144-52. 102. Yokoyama, T., et al., Epidemiological evidence that acetaldehyde plays a significant role in the development of decreased serum folate concentration and elevated mean corpuscular volume in alcohol drinkers. Alcoholism: Clinical and Experimental Research, 2005. 29(4): p. 622-630. 103. Bornstein, J., M.A. Rahat, and H. Abramovici, Etiology of cervical cancer: current concepts. Obstetrical & Gynecological Survey, 1995. 50(2): p. 146-54. 104. Castle, P.E., et al., An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiology, Biomarkers & Prevention, 2001. 10(10): p. 1021-7. 105. Singer, A., The uterine cervix from adolescence to the menopause. British Journal of Obstetrics & Gynaecology, 1975. 82(2): p. 81-99. 106. Autier, P., et al., Transformation zone location and intraepithelial neoplasia of the cervix uteri. British Journal of Cancer, 1996. 74(3): p. 488-90. 107. Bosch, F.X., et al., Risk factors for cervical cancer in Colombia and Spain. International Journal of Cancer, 1992. 52(5): p. 750-8. 108. Brinton, L.A., et al., Oral contraceptive use and risk of invasive cervical cancer. International Journal of Epidemiology, 1990. 19(1): p. 4-11. 109. Brinton, L.A., et al., Long-term use of oral contraceptives and risk of invasive cervical cancer. International Journal of Cancer, 1986. 38(3): p. 339-44. 110. Brinton, L.A., Oral contraceptives and cervical neoplasia. Contraception, 1991. 43(6): p. 581-95. 111. Piper, J.M., Oral contraceptives and cervical cancer. Gynecologic Oncology, 1985. 22(1): p. 1-14. 112. Auborn, K.J., et al., The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. International Journal of Cancer, 1991. 49(6): p. 867-9. 113. Arbeit, J.M., P.M. Howley, and D. Hanahan, Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 1996. 93(7): p. 2930-5. 114. Monsonego, J., et al., Estrogen and progesterone receptors in cervical human papillomavirus related lesions. International Journal of Cancer, 1991. 48(4): p. 533-9. 115. Chen, Y.H., L.H. Huang, and T.M. Chen, Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochemical & Biophysical Research Communications, 1996. 224(3): p. 651-9. 116. Lassise, D.L., et al., Invasive cervical cancer and intrauterine device use. International Journal of Epidemiology, 1991. 20(4): p. 865-70. 117. Schiff, M., et al., Contraceptive and reproductive risk factors for cervical intraepithelial neoplasia in American Indian women. International Journal of Epidemiology, 2000. 29(6): p. 983-90. 118. Peto, J., Cancer epidemiology in the last century and the next decade. Nature, 2001. 411(6835): p. 390-5. 119. Calle, E.E., et al., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine, 2003. 348(17): p. 1625-38. 120. Key, T.J., et al., Energy balance and cancer: the role of sex hormones. Proceedings of the Nutrition Society, 2001. 60(1): p. 81-9. 121. Albanes, D., Caloric intake, body weight, and cancer: a review. Nutrition & Cancer, 1987. 9(4): p. 199-217. 122. Wolk, A., et al., A prospective study of obesity and cancer risk (Sweden). Cancer Causes & Control, 2001. 12(1): p. 13-21. 123. Ursin, G., et al., Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case-control study (California, United States)[see comment]. Cancer Causes & Control, 1996. 7(3): p. 391-401. 124. Parazzini, F., et al., Risk factors for adenocarcinoma of the cervix: a case-control study. British Journal of Cancer, 1988. 57(2): p. 201-4. 125. Parazzini, F. and C. La Vecchia, Epidemiology of adenocarcinoma of the cervix. Gynecologic Oncology, 1990. 39(1): p. 40-6. 126. Brinton, L.A., et al., Epidemiology of cervical cancer by cell type. Cancer Research, 1987. 47(6): p. 1706-11. 127. Lacey, J.V., Jr., et al., Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer, 2003. 98(4): p. 814-21. 128. Lubitz, R.M., et al., Is obesity a barrier to physician screening for cervical cancer? American Journal of Medicine, 1995. 98(5): p. 491-6. 129. Wee, C.C., et al., Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care?[see comment]. Annals of Internal Medicine, 2000. 132(9): p. 697-704. 130. Moodley, M., et al., The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. International Journal of Gynecological Cancer, 2003. 13(2): p. 103-10. 131. Woodman, C.B., et al., Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet, 2001. 357(9271): p. 1831-6. 132. Deacon, J.M., et al., Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. British Journal of Cancer, 2000. 83(11): p. 1565-72. 133. zur Hausen, H., Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer, 2002. 2(5): p. 342-50. 134. Schlecht, N.F., et al., Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. Journal of the National Cancer Institute, 2003. 95(17): p. 1336-43. 135. Richart, R.M. and B.A. Barron, A follow-up study of patients with cervical dysplasia. American Journal of Obstetrics & Gynecology, 1969. 105(3): p. 386-93. 136. Cowan, F.M., et al., Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ, 1994. 309(6965): p. 1325-9. 137. Smith, J.S., et al., Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sexually Transmitted Diseases, 2001. 28(4): p. 187-94. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24215 | - |
dc.description.abstract | 中文摘要
研究一 台灣婦女感染人類乳突病毒的型別盛行率及其決定因子 背景:人類乳突病毒感染是子宮頸癌的必要因子,但是台灣婦女感染人類乳突病毒的型別盛行率及其決定因子的相關研究卻相當缺少。 方法:本橫斷調查之研究對象係選自1991-1992年間在台灣七鄉鎮市所收案的5487名婦女,利用聚合酵素連鎖反應及基因晶片雜交法檢測子宮頸細胞中的人類乳突病毒DNA 並加以定型,再採用邏輯式迴歸分析 (logistic regression)計算危險對比值 (odds ratio, OR) 及其95%信賴區間 (confidence interval, CI)。 結果:(薏竹: 請加入盛行率資料) 婦女感染人類乳突病毒的決定因子,包括第一次性經驗年齡、終生性伴侶數目、子宮內避孕器的使用、保險套的使用以及身體質量指數 (BMI)。 結論:台灣婦女感染人類乳突病毒的盛行率相當高,而其相關因子多半和性行為有關,加強民眾安全性行為的衛生教育,將可預防人類乳突病毒之感染。 研究二 人類乳突病毒16型DNA與血清標記與子宮頸癌之相關研究 背景:第16型人類乳突病毒是最常被探討的高危險人類乳突病毒之一,其生物標記又分成DNA及血清標記兩種,過去的研究多半只探討單一標記與罹患子宮頸癌危險性的相關,本研究同時探討第16型人類乳突病毒DNA與血清標記與子宮頸癌之相關。 方法:本重疊病例對照研究,包括從收案兩年後到2002年間,新發病的43名子宮頸癌原位癌以及侵襲癌病例,以及以年齡、居住地區、採檢時間配對的200名對照組婦女。利用聚合酵素連鎖反應及基因晶片雜交法檢測子宮頸細胞中的第16型人類乳突病毒DNA,利用酵素免疫法測定血清抗體,並以條邏輯式迴歸分析,計算發生子宮頸癌的危險對比值(odds ratio, OR)以及95%信賴區間(confidence interval, CI)。 結果:第16型人類乳突病DNA和抗體陽性都是對子宮頸癌的危險因子,其危險對比值(95%信賴區間)分別為25.0 (6.9-91.5) 以及6.3 (1.3-31.6)。在控制高危險型人類乳突病毒DNA陽性狀況後,只有教育程度和使用口服避孕藥是發生子宮頸癌的共同因子。 結論:第16型人類乳突病DNA和抗體陽性都是對子宮頸癌的危險因子。 | zh_TW |
dc.description.abstract | Abstract
Part I: Type-specific prevalence and determinants of Human papillomavirus infection among women in Taiwan Background:Infection with Human papillomavirus (HPV) is a necessary cause of cervical cancer. However, there were few studies to investigate the prevalence and determinants of HPV infection among women in Taiwan. Methods:In this cross-sectional survey, we enrolled 5487 women aged 30-64 years old from seven townships in Taiwan. Cervical cells collected at enrollment were tested for HPV genotypes by polymerase chain reactions and genechip hybridization. Logistic regression models were used to estimate odds ratio (OR) with its 95% confidence interval (CI) for each determinant of HPV infection. Result:The overall age-adjusted prevalence of HPV infection was 12.9%. Prevalence of HPV infection was significantly associated with the age at first sexual intercourse, number of lifetime sexual partners, use of intrauterine device, use of condom and body mass index. Conclusions:The prevalence of HPV infection is relatively high among women in Taiwan. As most determinants of HPV infection are related to sexual behavior, comprehensive health education on safe sexual activities is highly recommended. Part II: Associations between cervical cancer and biomarkers of HPV type 16 infection Background:HPV type 16 (HPV 16) was the most important high risk type of HPV. Biomarkers of HPV 16 infection include HPV DNA in cervical cells and antibodies against HPV 16 (anti-HPV 16) in serum, but there were few studies to investigate the combined effects of these two biomarkers on cervical cancer. Methods:This nested case control study included 43 cases of newly diagnosed cervical cancer (including carcinoma in situ and invasive carcinoma) and 200 unaffected controls matched with cases on age, residential township and date at enrollment. Cervical cells collected at enrollment were tested for HPV genotypes by polymerase chain reactions and genechip hybridization. Anti-HPV 16 was tested by enzyme-linked immunoassay. Conditional logistic regression models were used to estimate odds ratio (OR) with its 95% confidence interval (CI) for these two biomarkers separately and jointly. Results:A significantly increased risk of cervical cancer was associated with the positivity of HPV DNA and anti-HPV 16 showing OR (95% CI) of 25.0 (6.9-91.5) and 6.3 (1.3-31.6), respectively. Educational level and use of oral contraceptive were significantly associated with cervical cancer after adjustment for the infection of all high risk types of HPV. Conclusions:Positivity of both HPV 16 DNA in cervical cells and anti-HPV 16 in serum are important risk factors for cervical cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:18:43Z (GMT). No. of bitstreams: 1 ntu-94-R92842013-1.pdf: 479886 bytes, checksum: 9c0d2d48c05ffd2b4685a1342e317836 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 中文摘要I
英文摘要III 目錄V 圖表目錄VI 第一章 文獻探討1 第二章 究目的及假說、研究族群與資料收集10 第一節 研究目的及假說10 第二節 研究族群10 第三節 資料收集11 第三章 台灣婦女感染人類乳突病毒的型別盛行率及其決定因子13 第一節 研究方法13 第二節 統計方法13 第三節 研究結果13 第四節 討論43 第四章 人類乳突病毒16型DNA與血清標記與子宮頸癌之相關研究49 第一節 研究方法49 第二節 統計方法49 第三節 研究結果49 第四節 討論62 第五章 總結討論67 第六章 研究限制68 參考文獻69 | |
dc.language.iso | zh-TW | |
dc.title | 人類乳突病毒與子宮頸癌之分子流行病學研究 | zh_TW |
dc.title | Molecular Epidemiology of Human Papillomavirus and Cervical Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 游山林 | |
dc.contributor.oralexamcommittee | 謝長堯,孫建安,朱堂元 | |
dc.subject.keyword | 人類乳突病毒,子宮頸癌,盛行率,決定因子,人類乳突病毒16型, | zh_TW |
dc.subject.keyword | HPV,Cervical cancer,Prevalence,Determinants,HPV 16, | en |
dc.relation.page | 79 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2005-07-29 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 468.64 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。